Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox®) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum

2009 ◽  
Vol 112 (1) ◽  
pp. 35-39 ◽  
Author(s):  
Sheng-Mou Hsiao ◽  
Chi-An Chen ◽  
Ho-Hsiung Lin ◽  
Chang-Yao Hsieh ◽  
Lin-Hung Wei
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Trial ◽  
Pegylated Liposomal Doxorubicin ◽  
Front Line ◽  
Platinum Sensitive ◽  
Line Therapy

scholarly journals Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial

2006 ◽  
Vol 17 (6) ◽  
pp. 957-961 ◽  
Author(s):  
J. Sehouli ◽  
G. Oskay-Özcelik ◽  
J. Kühne ◽  
D. Stengel ◽  
H.-J. Hindenburg ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Trial ◽  
Pegylated Liposomal Doxorubicin ◽  
Multicenter Phase

Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer

2009 ◽  
Vol 19 (6) ◽  
pp. 1137-1141 ◽  
Author(s):  
B. L. Rapoport ◽  
D. A. Vorobiof ◽  
C. Slabber ◽  
A. S. Alberts ◽  
H. S. Hlophe ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Median Time ◽  
Median Survival ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Pegylated Liposomal Doxorubicin ◽  
Time To Progression ◽  
Overall Response ◽  
Platinum Sensitive

Objective:This phase II study assessed the activity and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin in relapsed ovarian cancer (ROC).Method:Forty women with platinum-sensitive and partially platinum-sensitive ROC were treated with PLD 50 mg/m2plus carboplatin area under the curve 5 every 28 days in this South African multicenter study. All patients who completed 3 cycles of chemotherapy were evaluated for response. Primary outcome was response in the intent-to-treat population.Results:Complete response was 35%, and partial response was 32.5% (overall response, 67.5%). Median time-to-progression was 11.9 months, and median survival was 30.0 months. Overall response was higher in platinum-sensitive (81%) versus partially platinum-sensitive patients (53%), as were median duration of response, median time-to-progression, and median survival. Treatment was well tolerated, with no grade 4 nonhematologic toxicities. Grade 3/4 hematologic toxicities included leukopenia (58%), neutropenia (55%), and thrombocytopenia (43%).Conclusion:Pegylated liposomal doxorubicin plus carboplatin is well tolerated and active in the treatment of platinum-sensitive and partially platinum-sensitive ROC.

Sign in / Sign up

Export Citation Format

Share Document